At the end of the latest market close, Chemomab Therapeutics Ltd. (CMMB) was valued at $20.00. In that particular session, Stock kicked-off at the price of $19.31 while reaching the peak value of $21.91 and lowest value recorded on the day was $18.60. The stock current value is $22.53.
Recently in News on June 10, 2021, Chemomab Announces Poster Presentation at the International Liver Congress 2021 (EASL). Chemomab Therapeutics, Ltd. (Nasdaq: CMMB), a clinical-stage biotech company focused on the discovery and development of innovative therapeutics for fibrosis-related diseases with high unmet need, today announced a poster presentation at the International Liver Congress 2021 (EASL), which is being held virtually on June 23-26, 2021. You can read further details here
Chemomab Therapeutics Ltd. had a pretty Dodgy run when it comes to the market performance. The 1-year high price for the company’s stock is recorded $168.80 on 02/10/21, with the lowest value was $15.18 for the same time period, recorded on 05/24/21.
Chemomab Therapeutics Ltd. (CMMB) full year performance was -2.34%
Price records that include history of low and high prices in the period of 52 weeks can tell a lot about the stock’s existing status and the future performance. Presently, Chemomab Therapeutics Ltd. shares are logging -86.65% during the 52-week period from high price, and 82.88% higher than the lowest price point for the same timeframe. The stock’s price range for the 52-week period managed to maintain the performance between $12.32 and $168.80.
The company’s shares, operating in the sector of Healthcare managed to top a trading volume set approximately around 1898401 for the day, which was evidently higher, when compared to the average daily volumes of the shares.
When it comes to the year-to-date metrics, the Chemomab Therapeutics Ltd. (CMMB) recorded performance in the market was -27.75%, having the revenues showcasing -71.46% on a quarterly basis in comparison with the same period year before. At the time of this writing, the total market value of the company is set at 201.80M, as it employees total of 3 workers.
Analysts verdict on Chemomab Therapeutics Ltd. (CMMB)
During the last month, 0 analysts gave the Chemomab Therapeutics Ltd. a BUY rating, 0 of the polled analysts branded the stock as an OVERWEIGHT, 0 analysts were recommending to HOLD this stock, 0 of them gave the stock UNDERWEIGHT rating, and 0 of the polled analysts provided SELL rating.
According to the data provided on Barchart.com, the moving average of the company in the 100-day period was set at 39.35, with a change in the price was noted -9.74. In a similar fashion, Chemomab Therapeutics Ltd. posted a movement of -29.13% for the period of last 100 days, recording 281,077 in trading volumes.
Total Debt to Equity Ratio (D/E) can also provide valuable insight into the company’s financial health and market status. The debt to equity ratio can be calculated by dividing the present total liabilities of a company by shareholders’ equity. Debt to Equity thus makes a valuable metrics that describes the debt, company is using in order to support assets, correlating with the value of shareholders’ equity The total Debt to Equity ratio for CMMB is recording 0.00 at the time of this writing. In addition, long term Debt to Equity ratio is set at 0.00.
Chemomab Therapeutics Ltd. (CMMB): Technical Analysis
Raw Stochastic average of Chemomab Therapeutics Ltd. in the period of last 50 days is set at 14.99%. The result represents downgrade in oppose to Raw Stochastic average for the period of the last 20 days, recording 66.88%. In the last 20 days, the company’s Stochastic %K was 60.80% and its Stochastic %D was recorded 58.24%.
Let’s take a glance in the erstwhile performances of Chemomab Therapeutics Ltd., multiple moving trends are noted. Year-to-date Price performance of the company’s stock appears to be encouraging, given the fact the metric is recording -27.75%. Additionally, trading for the stock in the period of the last six months notably deteriorated by -22.36%, alongside a downfall of -2.34% for the period of the last 12 months. The shares 17.23% in the 7-day charts and went up by 11.23% in the period of the last 30 days. Common stock shares were lifted by -71.46% during last recorded quarter.